A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

BACKGROUND: Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4). An extension study (TEMPO 4:4) showed continued delay in progression at 2 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Mader, Gregory, Mladsi, Deirdre, Sanon, Myrlene, Purser, Molly, Barnett, Christine L., Oberdhan, Dorothee, Watnick, Terry, Seliger, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578187/
https://www.ncbi.nlm.nih.gov/pubmed/36258169
http://dx.doi.org/10.1186/s12882-022-02956-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578187/
https://www.ncbi.nlm.nih.gov/pubmed/36258169
http://dx.doi.org/10.1186/s12882-022-02956-8

Ejemplares similares